The Readout Loud Podcast
1) 371: A gene therapy success in Huntington's and Trump's autism announcement
We bring on UniQure CEO Matt Kapusta to discuss the company's announcement this week that its one-time treatment for Huntington’s disease significantly slowed down the neurological condition in a key ...Show More
2) 370: Pharma sours on the U.K., plus biotech M&A's quiet roll
STAT's European correspondent Andrew Joseph calls in from the U.K. to the podcast to dissect why companies like Merck and GSK are putting their money elsewhere. We also discuss the Advisory Committe...Show More
3) 369: Trump, Chinese biotech, and an industry career reshaped by illness
Listeners of this podcast probably know pharma consultant Mike Rea for his annual ranking of drug company R&D productivity. But this week, he penned a poignant personal essay explaining how some medic...Show More
4) 368: New stakes in the vaccine dispute and a boost for biotech
Labor Day is in the rearview mirror, and that means Adam, Elaine, and Allison are all back to work. They take the pulse of the biotech market and discuss forthcoming data readouts at two sleep and lun...Show More
5) 367: The ouster of CDC's director, biotech venture firm rankings
We bring on Washington correspondent Chelsea Cirruzzo to explain the ouster of CDC Cirector Susan Monarez and the resignations of other top officials. We also chat about STAT's annual VC rankings rep...Show More
6) 366: Viking’s obesity flop, ‘pharma to table’ drug sales
On this week’s episode of “The Readout LOUD”: vikings. No, not the seafaring Norse people of the 10th century, or the Minnesota football team. The gang will discuss obesity drug developer Viking Thera...Show More
7) 365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended
We discuss the sudden return of Prasad and the mixed prospects for mRNA. Then, we invite STAT fellow Marissa Russo on to discuss the alternatives to animal testing, and why they’re the subject of hot ...Show More
8) 364: Closing a zombie biotech, and Lilly's disappointing obesity readout
We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us through why the company has decided to do this and h...Show More
9) 363: What Vinay Prasad’s ouster means for biotech and the FDA
This week’s show is focused on a single topic — the ouster of Food and Drug Administration official Vinay Prasad from his job running the agency’s biologics division. This surprising development came...Show More
10) 362: A mother’s perspective on Sarepta’s gene therapy halt
We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta’s decision to pull its treatment Elevidys from the market, following a request from the Food and...Show More